The online home for the primary care professionals managing patients with cardiovascular disease, diabetes and related diseases.

PRESCRIBING DPP-4 INHIBITORS Are there clinically relevant differences?

Publication date: Monday, 17 December 2012
Contributor(s): Professor Roger Gadsby

There are now four agents in the new class of glucose-lowering agents called dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) available in the UK. They are, in order of launch in the UK, sitagliptin, vildagliptin, saxagliptin and linagliptin. Several others are in the pipeline and are likely to be launched before long. This article will discuss their place in treating diabetes and the differences between them.

Category: Editorial
Edition: 2012
Contributor(s): Professor Roger Gadsby

Article search and filter